You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
- 2. Prospective evaluation of mpMRI-derived nomograms for detecting prostate cancer in PI-RADS v2.1 upgraded and non-upgraded lesions
- 3. FDA expands darolutamide indication for advanced prostate cancer
- 4. People with cancer face ‘ticking timebomb' due to NHS staff shortages
- 5. Advances in hepatic arterial perfusion chemotherapy for hepatic metastases
- 6. Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
- 7. BioNTech, Bristol Myers Squibb Team Up on China-Made Cancer Drug
- 8. Identification of risk factors for high-risk dedifferentiation in papillary thyroid carcinoma and construction of discriminative model
- 9. Survival prognosis evaluation in advanced breast cancer patients: a study on the application of the advanced lung cancer inflammation index
- 10. Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
Last updated at 22:50 GMT
Hot News Makers
Health/Pharma Companies
-
120499.70
-
85413.12
-
7609.07
-
7282.69
-
6223.70
-
5777.02
-
5454.31
-
5324.45
-
4954.49
-
4945.22
Drugs, Treatments, Trials
-
32114.82
-
15208.46
-
12716.47
-
10720.22
-
9512.54
-
8996.46
-
7377.17
-
5708.61
-
4575.94
-
4449.59
Last updated at 22:10 GMT
